Plaintiff
3 cases as plaintiff.
10x Genomics, Inc. (Nasdaq: TXG) is a publicly traded life science technology company founded in 2012. Headquartered in Pleasanton, California, the company designs and manufactures integrated systems for biological analysis. As of early 2026, 10x Genomics has over 1,100 employees and reported revenues of approximately $619 million for 2023. Its market capitalization was approximately $2.74 billion as of May 2026.
The company operates in the biotechnology sector, providing instruments, consumables, and software to analyze biological systems at high resolution. Its key product platforms—Chromium, Visium, and Xenium—enable single-cell, spatial, and in-situ analysis, which allows researchers to study individual cells and their spatial relationships within tissues. These technologies are used by academic institutions and pharmaceutical companies for research in fields such as oncology, immunology, and neuroscience. Major product lines facilitate single-cell gene expression, immune profiling, and epigenetics analysis.
As an operating company, 10x Genomics actively uses patent litigation to protect its technology. The company's sole tracked case is as a plaintiff, indicating a strategy of asserting its own patents rather than defending against infringement claims from non-practicing entities. This offensive posture is typical for technology companies engaged in direct competition.
The company's one tracked case, 10x Genomics, Inc. et al. v. Element Biosciences, Inc., was filed on May 8, 2026, in the U.S. District Court for the District of Delaware. In this suit, 10x Genomics and Harvard College allege that Element Biosciences' Aviti24 platform infringes on four patents related to spatial biology technology. Element Biosciences has stated it will "vigorously defend" against the allegations.
Watchlist
Email-only, free, anonymous. We'll notify you when 10x Genomics, Inc. files another patent-infringement lawsuit. One-click unsubscribe from any alert.
The lawsuit alleges that Element Biosciences' AVITI24 platform and Teton chemistry infringe upon the asserted patents. The plaintiffs seek a permanent injunction, ongoing royalties, and damages for past infringement.
This case involved infringement claims by 10x and Harvard, with Vizgen filing counterclaims for non-infringement, invalidity, and antitrust violations. The parties reached a settlement in early February 2025, resolving the global patent dispute.
This case involves a broader dispute over multiple spatial technology patents, including US 11,021,737. The case is ongoing, with proceedings previously linked to the related action against Vizgen.